Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00292981 · ClinicalTrials.gov registry record · Phase 3
C1 Esterase Inhibitor in Hereditary Angioedema (HAE)(Extension Study)
A Phase 3 study, sponsored by CSL Behring.
- Completed
- Registry status
- Phase 3
- Development phase
- 57
- Enrollment target
NCT00292981 is a Phase 3 study that has completed, run by CSL Behring. The registered enrollment target is 57 participants.
The verdict
NCT00292981, a Phase 3 study, has completed, sponsored by CSL Behring.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 57 participants
- Enrollment target
Study Summary
Hereditary angioedema (HAE) is a rare disorder characterized by congenital lack of functional C1 esterase inhibitor. If not treated adequately, the acute attacks of HAE can be life-threatening and may even result in fatalities, especially in case of involvement of the larynx.The planned extension study is designed to enrol subjects that participated in the pivotal study in order to provide them with C1-INH for treatment of acute HAE attacks for 24 months or until the licensing procedure for C1-INH is finalized, whatever comes first.
Interventions
- DRUG C1 Esterase Inhibitor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 57 participants |
| Start Date | 2005-08 |
| Est. Completion | 2010-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00292981
The ClinicalTrials.gov registry entry for NCT00292981 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 57 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CSL Behring, which has 71 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which C1 Esterase Inhibitor is the first listed.
NCT00292981 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00292981 about?
NCT00292981 is a clinical study titled "C1 Esterase Inhibitor in Hereditary Angioedema (HAE)(Extension Study)". Hereditary angioedema (HAE) is a rare disorder characterized by congenital lack of functional C1 esterase inhibitor. If not treated adequately, the acute attacks of HAE can be life-threatening and may even result in fatalities, especially in case of involvement of the larynx.The planned extension st...
What is the current status of trial NCT00292981?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 57 participants. The study started on 2005-08. Estimated completion is 2010-05.
What interventions are being tested in trial NCT00292981?
The interventions under investigation include: C1 Esterase Inhibitor (DRUG).
Who is sponsoring clinical trial NCT00292981?
This trial is sponsored by CSL Behring, which has 71 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.